Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapy.

doi:10.1073/pnas.2508762123

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapy.

Proceedings of the National Academy of Sciences of the United States of America - 28 Apr 2026

Robay Dimitri, Ackermann Ole, Laborde Laurent, Shi Xingyi, Oreglia Federico, Stump Ramona, Ciaghi Sabina, Galli Giorgio G, Holzer Laura, Villemin Lorraine, Wagner Joel, Wu Jincheng, Lee Lang Ho, Bossen Claudia, Mourikis Thanos P, Gabriel Millicent, Ruddy David, Yu Haiyan, Johannessen Cory, Ferretti Stephane, Costa Carlotta

Abstract excerpt

Non-small cell lung cancer (NSCLC) patients with tumors harboring STK11 mutations are resistant to standard of care anti-PD-1/PD-L1 blockade. For this patient population there are no currently available tailored treatments, underlying the critical need to discover effective therapeutic strategies. In this study, we dissected the molecular mechanisms responsible for STK11-mediated resistance to immune checkpoint...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to AMP-Activated Protein Kinases

Share to Carcinoma, Non-Small-Cell Lung

Share to Cyclic AMP Response Element-Binding Protein

Share to Drug Resistance, Neoplasm

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Protein Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 42018410
DOI: 10.1073/pnas.2508762123
PMCID: PMC13123801

Genes

CRTC2
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapy.PMID 42018410Read ↗

Precision Epigenetic Reprogramming: CoREST Inhibition Sensitizes STK11-Mutant Tumors to Immune Checkpoint Blockade Therapy.Semantic proximity Read ↗

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.Semantic proximity Read ↗

PCK2 inhibits lung adenocarcinoma tumor cell immune escape through oxidative stress-induced senescence as a potential therapeutic targetSemantic proximity Read ↗

Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.Semantic proximity Read ↗

CK2B Induces CD8+ T‐Cell Exhaustion through HDAC8‐Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti‐PD‐1 Therapy in Non‐Small‐Cell Lung CancerSemantic proximity Read ↗

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Semantic proximity Read ↗

Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.Semantic proximity Read ↗

Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activationSemantic proximity Read ↗

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.Semantic proximity Read ↗

STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC.Semantic proximity Read ↗

Pharmacological rescue of tumor intrinsic STING expression and immune response in LKB1-mutant lung cancer via the IAP-JAK regulatory axisSemantic proximity Read ↗

Oncogenic EGFR rewires STING-TBK1 immune machinery by tyrosine phosphorylation to license DNA damage toleranceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.